Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
暂无分享，去创建一个
E. Oki | Masato Nakamura | N. Sugimoto | S. Ishihara | T. Yoshino | A. Takashima | T. Nakajima | K. Shirao | T. Kajiwara | H. Ojima | H. Kawakami | H. Hara | H. Taniguchi | Y. Sunakawa | T. Terazawa | Y. Kuboki | M. Kotaka | J. Watanabe | T. Masuishi | A. Makiyama | N. Takenaka | Daisuke Ozawa | S. Morita | Y. Kagawa